CD274 and neoplasm: Most biomarker studies have relied on whole-exome sequencing or RNA sequencing (RNA-seq) of tumor samples, which provide a broad genetic overview and include biomarkers like programmed cell death-ligand 1 (PD-L1) (28), microsatellite instability (MSI) (29), and tumor mutation burden (TMB) (30).